COVID-19 vaccine sales boosted Pfizer earnings well past expectations in the fourth quarter, but the drugmaker is setting a lower-than-expected bar for 2022.
Join The Ecosystem
COVID-19 vaccine sales boosted Pfizer earnings well past expectations in the fourth quarter, but the drugmaker is setting a lower-than-expected bar for 2022.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.